Liu Zhenning, Roberts Thomas M
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Cell Cycle. 2006 Apr;5(7):675-7. doi: 10.4161/cc.5.7.2605. Epub 2006 Apr 1.
The PI3K-Akt pathway is frequently upregulated in human tumors. Recently, somatic mutations of PIK3CA, encoding p110alpha catalytic subunit of Class IA PI3Ks, have been found in various cancers. The two most common types of p110alpha mutants, those in the helical and kinase domains, have been shown to be very potent in Akt activation and oncogenic transformation by several groups. Notably these common mutations may not enhance recruitment of p110alpha to the plasma membrane where its substrates are located. We have investigated the effect of membrane localization on common PIK3CA tumor mutants via myristoylation. In addition we have studied a third class of less frequent mutants in the p85-binding domain, in an attempt to gain insight into p85's inhibitory effect on p110alpha. This article briefly reviews and extends the literature on mutant forms of p110alpha.
PI3K-Akt信号通路在人类肿瘤中经常上调。最近,在各种癌症中发现了编码IA类PI3Ks的p110α催化亚基的PIK3CA体细胞突变。p110α突变体的两种最常见类型,即螺旋结构域和激酶结构域中的突变体,已被多个研究小组证明在激活Akt和致癌转化方面非常有效。值得注意的是,这些常见突变可能不会增强p110α向其底物所在的质膜的募集。我们通过肉豆蔻酰化研究了膜定位对常见PIK3CA肿瘤突变体的影响。此外,我们还研究了p85结合结构域中第三类不太常见的突变体,以试图深入了解p85对p110α的抑制作用。本文简要回顾并扩展了关于p110α突变形式的文献。